cancer research uk cambridge centre early detection programme annual symposium · 2019-01-30 ·...
TRANSCRIPT
Cancer Research UK Cambridge Centre
Early Detection Programme Annual Symposium
Monday 28th January 2019 CRUK Cambridge Institute
Programme Speaker abstracts and symposium information
PROGRAMME CONTACT DETAILS [email protected] To join our mailing list, please contact us @CRUKCamEarlyDx Cancer Research UK Cambridge Centre Early Detection Programme c/o Hutchison-MRC Research Centre PO Box 197 Cambridge Biomedical Campus Cambridge, CB2 0XZ
UPCOMING EARLY DETECTION EVENTS Breakfast meeting“Cost effectiveness of screening for kidney cancer”, Dr Sabrina Rossi Thursday 14th February 2019 08:30 - 09:30 Clinical School Restaurant (takes place every other month) Multidisciplinary Networking event Topic focus: Liver cancer, Dr Matthew Hoare and Dr Andrea Murray Monday 25th March 2019 17:30 - 19:00 Clinical School seminar room 1 (takes place every other month) Early Detection Summer School “Discovery and Development of Diagnostics for Early Detection of Cancer” 15-18th July 2019 Robinson College, Cambridge For a full programme events listing, please visit our website.
Welcome to the CRUK Cambridge Centre
Early Detection Programme Annual Symposium 2019
10:30 Welcome & Early Detection Programme overview Professor Rebecca Fitzgerald, Co-Lead, Early Detection Programme and Professor of Cancer Prevention
10:45Keynote address: Risk stratified approaches to breast cancer screening/early detection Professor Per Hall, Professor of Medical Epidemiology, Karolinska Institute Chair: Professor Antonis Antoniou, Professor of Cancer Risk Prediction, Department of Public Health and Primary Care
11:30
Short presentations from postdocs in early detection research - competition winners Dr Caroline Watson, The evolutionary dynamics of clonal haematopoiesis Dr Christopher Smith, Comprehensive characterisation of cell-free tumour DNA in plasma and urine of patients with renal tumours Tommy Nyberg, Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: results from the prospective EMBRACE study Matthew Barclay, Statistical properties of the ‘early stage at cancer diagnosis’ indicator of the performance of commissioning organisations Chair: Dr Sarah Bohndiek, Co-Lead, Early Detection Programme and Reader in Biomedical Physics
12:15Poster session with prize award by the Programme Steering Committee and networking lunch Posters on the early detection of cancer will be on display in the atrium and gallery during the networking lunch. The poster prize will be judged by the Early Detection Programme Steering Committee and presented by Professor Gilbertson in the closing session.
13:45
Keynote address: Development of current and future screening programmes Professor Robert Steele CBE, Chair of UK the National Screening Committee, Senior Research Professor Surgical Oncology, University of Dundee Chair: Dr Wendy Alderton, Programme Manager of the Early Detection Programme
14:30What will the early detection of cancer look like in 20 years’ time? Presentations from three working groups convened in advance Chair: Dr Andy Richards CBE, Biotechnology entrepreneur and investor
15:15 Concluding remarks and poster prizes Professor Richard Gilbertson, Director of the CRUK Cambridge Centre
Annual Symposium Programme
10:45 - Keynote address: Risk stratified approaches to breast cancer screening/early detection
Professor Per Hall Per is a medical oncologist by training. He currently holds the Chair at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. He is also honorary consultant physician at the Department of Oncology, Södersjukhuset, Stockholm,
Sweden. His research interest is focused on breast cancer screening and prevention. Over the last ten years he has established the Karma Cohort, a prospective screening cohort of approximately 70,000 women.
Professor Antonis Antoniou (session chair) Antonis’ main research interests in the Department of Public Health and Primary Care lie in the development of statistical modelling techniques to address clinical questions, and the development of risk prediction tools for use in clinical practice. The focus of Antonis’ lab is on
the development and evaluation of risk prediction models for familial breast, ovarian, prostate and other common cancers and the characterisation of cancer risks for genetically susceptible individuals, such as those carrying mutations in the BRCA1, BRCA2, PALB2, RAD51C and RAD51D genes.
Speaker biographies 10:30 - Welcome
Professor Rebecca Fitzgerald Rebecca is Professor of Cancer Prevention at the University of Cambridge and Co-Lead of the Early Detection Programme at the CRUK Cambridge Centre. Rebecca combines her work as a clinical gastroenterologist at Addenbrooke’s with running a
research programme at the MRC Cancer Unit. She has devoted her career to understanding the earliest steps of cancer development and how we can use this knowledge to develop clinical tools to diagnose oesophageal and gastric cancer early. Rebecca is keen to accelerate the development and adoption of new methods for the early detection of cancer.
11:30 - Short presentations from postdocs in early detection research - competition winners The evolutionary dynamics of clonal haematopoiesis
Dr Caroline Watson Caroline is a Clinical Research Fellow studying for a PhD in Jamie Blundell’s lab in the Early Detection Programme. She completed her medical training at the University of Oxford in 2010 and started her Haematology specialist training in Oxford in 2014. She moved to Cambridge in
2017 when she started her PhD and is using quantitative models and deep sequencing techniques to study the somatic evolution associated with healthy blood production (clonal haematopoiesis) and how this is perturbed in individuals who develop blood cancers. Comprehensive characterisation of cell-free tumour DNA in plasma and urine of patients with renal tumours
Dr Christopher Smith Prior to joining the Rosenfeld lab four years ago, Chris studied the genetics and pharmacogenetics of colorectal cancer at Cardiff University. In his current post, he is studying the application of ctDNA to non-invasive cancer detection, to determine patient response to treatment
and to track tumour evolution. Chris also has an interest in studying the bio-physical properties of cell-free DNA in order to unlock further clues that might add to our ability to use ctDNA as a robust biomarker.
Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: results from the prospective EMBRACE study
Tommy Nyberg Tommy is currently in the third year of his PhD at the Centre for Cancer Genetic Epidemiology (Department of Public Health and Primary Care). The aim of his PhD project is to develop and validate a comprehensive risk prediction model for a man’s future risk of developing
prostate cancer, based on genetic factors, explicit cancer family history and other risk factors. To do this, he is working with some of the largest nationwide UK datasets for prostate cancer, including the family-based UKGPCS study and the prospective EMBRACE study. Statistical properties of the ‘early stage at cancer diagnosis’ indicator of the performance of commissioning organisations
Matthew Barclay Matthew’s PhD research at THIS. Institute investigates how to measure healthcare quality, particularly the use of composite indicators. As a statistician he works mainly with cancer registry data and is currently investigating risk of second primary cancers. He previously worked as an
analyst for the National Cancer Intelligence Network and holds an honorary contract with the Public Health England National Cancer Registration and Analysis Service.
Dr Sarah Bohndiek (session chair) Sarah is Co-Lead of the CRUK Cambridge Centre Early Detection Programme. She is a Reader in Biomedical Physics and a Group Leader of a lab that operates jointly between the Department of Physics and the Cancer Research UK Cambridge Institute. Sarah’s lab develops
novel imaging technologies for early cancer detection and to better understand cancer therapy response.
12:15 - Poster session and networking lunch Dr Daniel Barnes, Department of Public Health & Primary Care¹ Polygenic risk scores and breast cancer risk for BRCA1 and BRCA2 mutation carriers Claudia Buhigas, University of East Anglia Understanding why prostate cancer is multifocal Maribel Lara Chica, Cancer Molecular Diagnostics Lab¹ DIRECT study: DLBCL Interim Response Evaluation for Customised Therapy Wendy Cooper, Cancer Research UK Cambridge Institute¹ Towards earlier diagnosis in women at high risk of breast and ovarian cancer: The BrOvED study Joe Dennis, Centre for Cancer Genetic Epidemiology¹ Identifying rare copy number variants from genotyping arrays Nina Friesgaard Obro, Stem Cell Institute¹ Serum GRO-α and EGF levels predict transformation in myeloproliferative neoplasms Estela Gonzalez-Gualda, Department of Oncology¹ Detrimental effects of chemotherapy-induced senescent cells in lung cancer progression Dr Xiaodun Li, MRC Cancer Unit¹ Derivation of oesophageal organoids to recapitulate the heterogeneity of primary tumours and provide a model system for precision therapeutics Dr Liz Moore, Cancer Research UK Cambridge Centre¹ Improving the detection of high-grade serous ovarian cancer using circulating tumour DNA
Dr Annalisa Mupo, Cancer Molecular Diagnostics Lab¹ Characterising T-cell receptor repertoires in cancer Dr Marta Paez-Ribes, Department of Oncology¹ Novel tools for lung cancer early diagnosis and therapy Dr Gahee Park, Department of Oncology¹ Detecting aggressive prostate cancers early by integrating multiple tumour-specific markers in cell-free DNA Dr Sabrina Rossi, Department of Oncology¹ A decision analysis of screening for renal cancer using focused renal ultrasound Miranda Townsend, Department of Radiology¹ BrAID: Breast Screening; Risk Adaptive Imaging for Density Aditi Vedi, Department of Haematology¹ Functional role of DNMT3A pre-leukemic mutations in haematopoietic stem and progenitor cells Matthew Vithayathil, MRC Cancer Unit¹ Combination of autofluorescence imaging and confocal laser endomicroscopy for the early diagnosis of neoplasia in Barrett’s oesophagus (ACE-B Trial) Dr Martyn Webb, Faculty of Medicine and Health, University of East Anglia Analysis of urine expression biomarkers to detect prostate cancer Xin Yang, Department of Public Health & Primary Care¹ Cancer risks in PALB2 mutation carriers - an international study of 524 families ¹ University of Cambridge
13:45 - Keynote address: Development of current and future screening programmes
Professor Robert Steele CBE Robert’s main interests are the treatment of and screening for colorectal cancer. Having led the UK demonstration pilot that was used to inform the decision to introduce national screening programmes throughout the United Kingdom, at present he is the Clinical Director
of the Scottish Colorectal Cancer Screening Programme, and has published extensively in this area. He has chaired several NHS QIS and HIS groups related to colorectal cancer and colorectal cancer screening and he chaired the SIGN group that developed the latest set of colorectal cancer guidelines. In 2016, he was appointed as Independent Chair of the UK National Screening Committee. In 2017 he was awarded an Honorary Membership of the Faculty of Public Health and was elected to the Fellowship of the Royal Society of Edinburgh. In 2018 he was elected to the Fellowship of the Academy of Medical Sciences and was awarded a CBE in the Queen’s Birthday Honours List.
Dr Wendy Alderton (session chair) Wendy is the Early Detection Programme Manager at the CRUK Cambridge Centre. A pharmacologist by training, Wendy has over 20 years of experience in cancer diagnostics, pre-clinical drug discovery and development in oncology and other therapeutic areas in biotechnology
and pharma companies. Wendy has previously held positions at Abcodia Ltd, Summit plc, PIramed Ltd, Millennium Pharmaceuticals, UK and GlaxoSmithKline.
14:30 - What will the early detection of cancer look like in 20 years’ time?
Dr Andy Richards CBE (session chair) Andy is an entrepreneur and investor with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is Chairman of Arecor, Congenica, Abcodia, Closed Loop Medicine and The Babraham Research Campus and is a Director of
Silence Therapeutics plc, Ieso Digital Health Ltd, and Owlstone Medical. He is an advisor to several investment funds including Cambridge Innovation Capital and the UCL Technology Fund and was, until recently, a director of Cambridge University Hospitals NHS Foundation Trust. Andy is a Member of Cancer Research UK and has been a director of Cancer Research Technology since 2003, he is also on the investment committee of the Seed Fund. GROUP 1, LED BY JAMIE BLUNDELL Estela Gonzalez-Gualda, PhD student Muñoz-Espín LabDepartment of Oncology Dr Gahee Park, Postdoc Massie LabDepartment of Oncology Dr Jamie Blundell, Early Detection Programme Group Leader Department of Oncology Dr Caroline Watson, PhD student Blundell LabDepartment of Oncology Joey Wilson, PhD student Muñoz-Espín LabDepartment of Oncology
Marta Wylot, PhD student Griffin labDepartment of Biochemistry GROUP 2, LED BY CHRIS HODKINSON Andrew Baker, PhD student Muñoz-Espín and Fruk LabsDepartment of Chemical Engineering and Biotechnology
Chris Hodkinson, VP Business Development Owlstone Medical Ltd Robert Hanson, CRUK Cambridge Centre MRes+ PhD ProgrammeDepartment of Oncology Dr Owain Jones, Clinical Research AssistantDepartment of Public Health and Primary Care Dr Marije van Melle, Postdoc CanTest collaborativeDepartment of Public Health and Primary Care Dr Valerie Sills, CanTest Programme ManagerDepartment of Public Health & Primary Care GROUP 3, LED BY PHIL JEWSBURY Calvin Cheah, Laboratory Informatics Developer Fitzgerald LabMRC Cancer Unit Alexandru Grigoroiu, PhD student Bohndiek LabDepartment of Physics Dr Phil Jewsbury, Senior Project Director AstraZeneca Oncology
Dr Neus Masque-Soler, Postdoc Fitzgerald LabMRC Cancer Unit Dr Karol Nowicki-Osuch, Postdoc Fitzgerald LabMRC Cancer Unit VOTING To cast your vote for the group with the most compelling vision at the end of this session, please visit www.menti.com. Enter code 77 06 80 to vote. 15:15 - Concluding Remarks
Professor Richard Gilbertson Richard Gilbertson trained as a paediatric oncologist in the UK before moving in 2000 to St. Jude Children’s Research Hospital, USA where he served as Scientific and Comprehensive Cancer Center Director, Executive Vice President and Lillian R. Cannon Endowed Chair. In August
2015, he moved back home to England where he chairs the Department of Oncology and directs the CRUK Cambridge Centre at Cambridge University. His laboratory research is focused on understanding the link between normal development and the origins of cancer, particularly brain tumors.
